developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD
Building complete iPSC-Gene Editing platform for production of iPSC-derived products for gene and cell therapy research and development